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Irradiation of blood components with ionizing radiation generated by a speciﬁc device is
recommended to prevent transfusion-associated graft-versus-host disease. However, a lin-
ear  accelerator can also be used in the absence of such a device, which is the case of the
blood bank facility studied herein. In order to evaluate the quality of the irradiated packed
red  blood cells, this study aimed to determine whether the procedure currently employed
in  the facility is effective in inhibiting the proliferation of T lymphocytes without damaging
blood components.
The proliferation of T lymphocytes, plasma potassium levels, and the degree of hemolysis
were evaluated and compared to blood bags that received no irradiation. Packed red blood
cell bags were irradiated at a dose of 25 Gy in a linear accelerator. For this purpose, a container
was  designed to hold the bags and to ensure even distribution of irradiation as evaluated by
computed tomography and dose-volume histogram.
Irradiation was observed to inhibit the proliferation of lymphocytes. The percentage of
hemolysis in irradiated bags was slightly higher than in non-irradiated bags (p-value >0.05),
but  it was always less than 0.4% of the red cell mass. Although potassium increased in both
groups, it was more pronounced in irradiated red blood cells, especially after seven days of
storage, with a linear increase over storage time.
The ﬁndings showed that, at an appropriate dosage and under validated conditions, the
irradiation of packed red blood cells in a linear accelerator is effective, inhibiting lymphocyte
proliferation but without compromising the viability of the red cells.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
is correlated to a high mortality rate. The main mechanismntroductionransfusion-associated graft-versus-host disease (TA-GvHD)
s a rare and acute delayed transfusion reaction which occurs
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after the transfusion of blood components; this complicationberaba, MG, Brazil.
for the occurrence of TA-GVHD is the transfer of T lym-
phocytes from the blood donor that damage and promote
a response in the tissues of the recipient. After recognizing
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.
with a nominal power of 6 MV.
Upon conﬁrmation of the irradiation of the bags by the radi-
ation indicators, ten bags from the total of 42 irradiated PRBC154  rev bras hematol hem
host tissues as foreign, the cytokines released by trans-
fused T lymphocytes, such as interleukin-1 (IL-1) and tumor
necrosis factor (TNF), drive an inﬂammatory response. These
cytokines activate inﬂammatory cells, including natural killer
(NK) cells, macrophages, and other T lymphocytes, resulting
in the destruction of host tissues thereby causing TA-GVHD.1,2
Another mechanism for the occurrence of TA-GVHD occurs
through donor-recipient HLA incompatibility.3 The develop-
ment of this transfusion reaction appears to relate to the
number and viability of T lymphocytes transfused in blood
components (although this number is not yet known), to the
level of immunosuppression of the patient, and to the extent
that antigens of the HLA system are common to both the donor
and recipient.4,5 Therefore, the greater the number of blood
components received, the greater the chance of TA-GVHD
occurring in at-risk patients.
In susceptible patients, TA-GVHD occurs when the number
of viable transfused lymphocytes is more  than 1 × 104 cells/kg
of body weight.3,5 It is known that non-leukodepleted packed
red blood cell (PRBC) bags have approximately 2–3 × 109 leuko-
cytes, whereas leukodepleted PRBC bags have from 2–3 × 106
leukocytes. Therefore, even leukodepletion is not able to pro-
tect these patients from TA-GVHD.3,6 In situations in which
the patient has a healthy immune system, lymphocytes are
destroyed. However, in immunosuppressed patients, these
cells are not destroyed by the recipient’s immune system and
so after proliferation and producing cytokines, the lympho-
cytes may cause a TA-GvHD-related inﬂammatory response.
Thus, the only effective method to prevent this disease com-
pletely is to inactivate donor lymphocytes by irradiating blood
components.
Determination No. 34 of the Ministry of Health of
Brazil/National Health Surveillance Agency (ANVISA) states
that the irradiation of blood and blood components should
be performed in a speciﬁc cell irradiator, and that when this
equipment is not available, irradiation can be carried out in
a linear accelerator used for radiation therapy.7 Using linear
accelerators instead of cell irradiators has been the subject
of discussion among authors. Although Vetter and Dodd con-
sider the performance of both methods to be similar,8 dose
uniformity may fail to meet the quality standards in linear
accelerators if the method is not standardized. This was also
reported by Janatpour et al. on comparing the irradiation of
blood components with X-rays and gamma-rays.9 Bashir et al.
demonstrated similar effects in the dosage of potassium and
in the degree of hemolysis in red blood cells subjected to X-rays
and gamma radiation, and suggested employing linear accel-
erators in the place of radioactive equipment due to the lower
maintenance cost and personnel training, and the dangers of
the inappropriate use of cesium.10
Radiation protocols for linear accelerators describe a wide
range of types and sizes of containers to be used during radi-
ation. Protocols also differ in respect to the distance between
the container and the radiation source, the quantity of bags to
be irradiated by each procedure, and the range of results.11,12
Proper irradiation should provide homogeneous distribution
of radiation inside the container used, resulting in inhibition
of lymphocyte proliferation and lower levels of hemolysis than
established by regulatory bodies.13 The PRBC units produced
in the Regional Blood Center of Uberaba (HRU) are irradiated 2 0 1 5;3  7(3):153–159
in a clinical linear accelerator in the Radiotherapy Depart-
ment of the Hospital de Clínicas of the Universidade Federal
do Triângulo Mineiro (UFTM). This study aimed to evaluate the
efﬁciency of irradiation of PRBCs and possible damage to red
blood cells using this method.
Methods
Standardization  of  the  method  and  irradiation  of  packed
red blood  cells
A 30 cm × 30 cm × 15 cm polycarbonate container was
designed with a 0.5 cm wall thickness big enough to hold
up to 18 PRBC bags (Figure 1). When fewer than 18 bags are
being processed, a special lid was created to reduce the size
inside the container in order to better control irradiation.
A 0.6-mL TN30013 waterproof Farmer ionization chamber
coupled to a T10010 Unidos E electrometer (PTW Freiburg)
jointly calibrated by the Brazilian Institute of Energy and
Nuclear Research (IPEN) were used to measure the dose in the
middle of the container. A computed tomography (CT) of the
container was performed to provide images for the Eclipse
three-dimensional treatment planning system. The analyti-
cal anisotropic algorithm (AAA) was used to calculate dose
distribution in the irradiated material including identifying
regions of uneven irradiation. Radiation indicators (RadTag®
RTG 15, RadTag Technologies, Alberta, Canada) were placed
on each bag to detect irradiation doses of from 15 to 50 Gy.
Four irradiation procedures involving ten or 12 PRBC bags
each were performed at a total dose of 25 Gy in the parallel
opposed ﬁelds of a Clinac 600TM linear accelerator (Varian)Figure 1 – Polycarbonate container designed to irradiate
packed red blood cell bags.
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Figure 2 – Tomographic image of the container after the
irradiation process. Dose distribution was homogenous inrev bras hematol hemot
ags were randomly taken for testing. Ten non-irradiated bags
ere used as control. Samples of 20 mL  were collected from
ach irradiated and non-irradiated bag to measure potassium
evels and to evaluate the degree of hemolysis on Days 1, 7,
4, 21 and 28. Day 1 (D1) was deﬁned as the day previous to
ag irradiation. Another 10 mL  sample was collected to com-
are the lymphocyte proliferation and apoptosis before and
 h after the irradiation process.
ulture  of  mononuclear  cells  of  the  packed  red  blood  cell
ample  to  evaluate  cell  proliferation
he proliferation rate of peripheral blood mononuclear cells
PBMCs) was assessed by labeling with carboxyﬂuorescein
iacetate succinimidyl ester (CFSE) and subsequent culture
timulated by phytohemagglutinin. PBMCs were isolated from
RBC by Ficoll-Hypaque separation. The cells were incubated
ith 5 M CFSE at room temperature in the dark for ﬁve
inutes and after 5% fetal bovine serum (FBS) was added.
ubsequently, they were washed in complete Roswell Park
emorial Institute (RPMI) medium with 10% FBS, and then
 × 105 cells were transferred to a 96-well plate to which
 g/mL phytohemagglutinin (SIGMA Chemical Co., St. Louis,
SA) was added. Some cells were maintained without the
ddition of the stimulus in order to determine basal ﬂuo-
escence. The samples were incubated for 72 h at 37 ◦C in
% carbon dioxide, and then the cells were collected and
esuspended in Dulbecco’s Phosphate-Buffered Saline solu-
ion (DPBS) for ﬂow cytometry analysis (25,000 events/tube)
sing a FACSCalibur ﬂow cytometer (BD, USA). The percent-
ge of cell proliferation was determined by subtracting the
timulated CFSE-labeled cell count from control basal ﬂuores-
ence (cells labeled with CFSE, but without stimulation). All
rocedures were performed under sterile conditions.
tatistical  analysis
t ﬁrst, the variables were subjected to descriptive analysis
sing measures of centrality and dispersion. The Shapiro–Wilk
est was used to test all variables for normality, whereas
artlett’s test was used to test homogeneity of variance of
ndependent groups (irradiated and non-irradiated). Due to
on-normality and non-homogeneity of variances for some
ariables in the groups, nonparametric analysis of variance
as performed using the Mann–Whitney test to compare
roups, whereas the Friedman test, Kendall’s coefﬁcient of
oncordance and simple linear regression were used to ana-
yze potassium levels and hemolysis over time. Lymphocyte
roliferation was evaluated by comparing the proliferation
ates obtained before and after irradiation using the paired
ilcoxon test. An alpha error of 5% was considered acceptable
p-value <0.05) for all tests.
esultsen irradiated bags and ten non-irradiated bags were ana-
yzed by comparing the proliferation rates, potassium levels,
nd the degree of serum hemolysis between the two groups.the central section of the tomography (yellow line).
Distribution of ionizing radiation was also evaluated for the
irradiated bags.
Evaluation  of  the  irradiation  procedure
Dosimetry showed that the calibration factor of the device met
the required factor, that is, 1 cGy/MU. Dose distribution was
homogenous in the central section of the CT (Dose = 25 Gy)
(Figure 2). A region where the dose reached 26.25 Gy was also
observed; this is a variation of 5% above the recommended
dose. Analysis of the histogram (Figure 3) shows that the
average dose was 28.12 Gy. The ﬁgure clearly shows that the
minimum dose was 24.37 Gy and the maximum dose was
29.32 Gy. Irradiation of all the ten irradiated PRBC bags was
conﬁrmed by RadTag® RTG 15 labels.
Efﬁciency  of  the  irradiation  process
Regarding the proliferation of lymphocytes, the median pro-
liferation index was 29.8% before irradiation, and 0.5% after
irradiation (p-value = 0.005; Figure 4).
Storage  lesions
The potassium levels (mmol/L) for irradiated and non-
irradiated bags during the storage time are shown in Table 1.
Over storage days, a signiﬁcant increase in potassium levels
was observed (p-value <0.0001; Friedman test) both in the non-
irradiated and irradiated groups, with medians of 61.5 mmol/L
and 89.2 mmol/L after 28 days of storage, respectively. A strong
linear correlation with the storage time (r = 1 in both cases)
was also observed. After adjusting the linear regression model,
there was an average increase of 12.96 mmol/L in potassium
levels in the non-irradiated group for every week of stor-
age. For the irradiated group, the increase was even higher:
18.69 mmol/L for each week of storage. On Day 7, potassium
levels of the non-irradiated group were signiﬁcantly lower
than in and irradiated group (p-value = 0.0002).
The percentages of hemolysis, vis-à-vis PRBC storage days
and bag irradiation, are shown in Table 2. There was a
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Figure 3 – Cumulative dose histogram.
Table 1 – Potassium levels (mmol/L) in respect to storage day and bag irradiation.
Bag irradiation Storage day n Median Mean (min–max) Standard deviation
Non-irradiated D1 10 5.05 6.85 (4.80–15.10) 3.66
D7 10 26.85 28.28 (24.30–34.30) 3.65
D14 10 39.05 40.89 (35.40–49.80) 5.21
D21 10 51.70 50.97 (44.40–58.60) 4.68
D28 10 61.50 60.31 (52.90–67.90) 5.50
Irradiated D1 10 5.85 11.05 (4.60–29.90) 8.59
D7 10 44.80 47.59 (38.00–59.70) 7.97
D14 10 71.90 71.94 (54.70–81.10) 7.82
D21 10 82.60 80.79 (63.50–92.50) 8.49
89.20D28 10 
signiﬁcant increase in hemolysis (p-value <0.0001; Friedman
test) over time both for the non-irradiated and irradiated
groups with a strong linear correlation with storage time
(r = 0.74 and r = 1, respectively). After adjusting the linear
regression model, an average increase of 0.0246% in hemolysis
per week of storage was observed in the non-irradiated group;
this was higher in the irradiated group (0.044%). However the
differences between the non-irradiated and irradiated groups
were not signiﬁcant (p-value > 0.05) at any storage time, and at
no time hemolysis was higher than 0.4%.
Table 2 – Hemolysis (%) in relation to the storage day and bag ir
Bag irradiation Storage day n Media
Non-irradiated D1 10 0.04
D7 10 0.07
D14 10 0.08
D21 10 0.11
D28 10 0.13
Irradiated D1 10 0.04
D7 10 0.07
D14 10 0.09
D21 10 0.15
D28 10 0.2087.89 (70.60–99.00) 7.53
Discussion
Due to underreporting of transfusion reactions in Brazil, the
incidence and prevalence of TA-GVHD are not yet fully known.
In the UK, according to the Annual SHOT Report of 2011, no
cases of TA-GVHD were reported from 2001 to 2011, unlike
what occurred between 1996 and 2001, when 13 cases were
recorded.14 In Japan, a country considered to have a high
prevalence of this transfusion reaction, there have been no
radiation.
n Average (min–max) Standard deviation
 0.06 (0.02–0.19) 0.05
 0.07 (0.05–0.11) 0.02
 0.08 (0.04–0.11) 0.02
 0.11 (0.06–0.18) 0.04
 0.16 (0.10–0.27) 0.06
 0.04 (0.02–0.05) 0.01
 0.07 (0.04–0.10) 0.02
 0.10 (0.05–0.16) 0.04
 0.16 (0.07–0.24) 0.06
 0.22 (0.11–0.39) 0.10
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Figure 4 – Pre- and post-irradiation pattern of lymphocyte
proliferation. Cell proliferation was determined by
subtracting carboxyﬂuorescein diacetate succinimidyl ester
labeling from control basal ﬂuorescence – cells labeled with
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the irradiation procedure had taken place. Even though thisFSE, but without stimulation.
ases since 2000 according to data published by the Safety Vig-
lance Division, Blood Service Headquarters of the Japanese
ed Cross Society.15 However, 57 cases were conﬁrmed out
f 232 suspected cases from 1993 to 1999. The decrease in
he frequency of this transfusion reaction is attributed to
he implantation of blood component irradiation between
998 and 1999, thereby demonstrating the importance of this
rocedure.15 The main goal of the Ministry of Health through
NVISA has been to understand the mechanisms of these
ransfusion reactions in order to propose measures to pre-
ent their occurrence, as well as to ensure the effectiveness
f hemotherapy and the safety of both blood donor and
ecipient.7
The reason to prevent this transfusion reaction using irra-
iated PRBCs in susceptible patients is the ineffectiveness
f treating this complication. Medications such as corti-
osteroids, immunoglobulins, anti-thymocyte globulin, and
ranulocyte-macrophage colony-stimulating factor are not
ffective and so the only option is prevention by the irradi-
tion of blood components.16,17 Ionizing radiation destroys
he DNA of lymphocytes, preventing their proliferation and,
hus, reducing the production of cytokines produced in this
rocess.2 The equipment recommended for the irradiation of
ellular blood components is a compact gamma-ray irradiator
peciﬁcally designed for this purpose. Nonetheless, its high
ost and the use of radioactive material hinder its use in Brazil,
o it has been successfully replaced by the linear accelerator, a
rocedure which is accepted by Brazilian regulations.7 Regard-
ess of the method, what is really crucial is that the procedure
s validated. The recommended radiation dose is 25 Gy, a dose
hich is considered adequate to inactivate lymphocytes.18his dose should not be lower than 15 Gy, because this would
ot inhibit lymphocyte proliferation, nor should it be higher
han 50 Gy, as there is a risk of severe red blood cell damage.7 1 5;3  7(3):153–159 157
Both gamma rays and X-rays have been studied over the years,
and there seems to be no difference between the results.9,10
One of the key requirements for effective irradiation is the
homogeneous distribution of radiation inside the container
that contains the bags being irradiated. Thus, the ﬁrst stage of
this study aimed to standardize the procedure. Firstly, a con-
tainer, which would eliminate as far as possible air around
the PRBC bags, was developed, as air can cause an uneven dis-
tribution of photons leading to a heterogeneous, anisotropic
distribution of the radiation.
The container used in this study minimized the presence of
air, which may, in part, explain the homogeneous distribution
of the dose. Other studies found different kinds of containers
were effective.11,12 Another factor which was important for
the even dose distribution in this study, as observed by Patton
and Skowronski,11 was that irradiation used parallel oppos-
ing ﬁelds. Two studies employing the single-ﬁeld technique
reported different results; one had homogeneous distribution
of radiation12 and the other a heterogeneous distribution.19
Regarding procedure validation, several studies used dif-
ferent methodologies thereby impeding comparisons of the
effectiveness of protocols. Pinnarò et al. validated their radi-
ation procedure based only on dosimetry measurements of
irradiated blood components.12 On the other hand, Patton
and Skowronski and Bashir et al. assessed only the potas-
sium levels and the degree of hemolysis to demonstrate the
effectiveness of radiation in a linear accelerator.10,11 Goes
et al. studied the proliferation of lymphocytes irradiated with
Cobalt-60, and did not ﬁnd proliferation of these cells at a dose
of 25 Gy using a limiting dilution assay.20 Furthermore, Pel-
szynski et al. did a series of experiments using red cell units
irradiated within 24 h after collection. They found that 15 Gy
inactivated >4 log10 of T cells, but viable T cells were detected
in all experiments. However, when they used 25 or 30 Gy, no
T-cell growth (>5 log10 depletion) was detected.21
In this study, we  used CT converted into a dose volume his-
togram to evaluate dose homogeneity. The difference between
these methods is that CT produces cross-sectional images of
tissue for analysis, whereas the histogram evaluates the total
irradiated volume. The dose distribution in the irradiated ves-
sel was found to be homogeneous in the central tomographic
section of the container, with a region where the dose reached
26.25 Gy – more  than the recommended minimum of 25 Gy –
and a variation of 5% of the prescribed dose; this is in accor-
dance with the planning recommended by the International
Commission on Radiation Units and Measurements,22 which
recommends doses ranging from −5% to +7% of the prescribed
dose as satisfactory planning.
The dose volume histogram showed that the dose of 25 Gy
was sufﬁcient to uniformly irradiate the entire area occupied
by the PRBC bags. These CT and histogram results showed that
the dose in none of the regions of the container was lower
than 15 Gy or higher than 50 Gy, as determined by Brazilian
regulations.7 Another important aspect of blood component
irradiation is the conﬁrmation that the irradiation occurred.23
In this study, the use of RadTag® RTG 15 labels ensured thatlabel is not a dosimeter, it detects whether irradiation has
occurred, thus ensuring a high quality process, as previously
demonstrated.11
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The efﬁcacy of radiation was demonstrated by a signiﬁ-
cant reduction in lymphocyte proliferation in irradiated PRBCs
(29.8% pre-irradiation versus 0.5% post-irradiation). The ﬂuo-
rescence emission observed in the cytometry of lymphocytes
in the irradiated bags (0.5%) may have been caused by the pres-
ence of doublets or aggregates or even DNA fragments from
these cells, but not by transformed lymphocytes.24 There-
fore, this and the proof that an effective radiation dose was
delivered7,18 shows that this method prevents the onset of TA-
GVHD in patients transfused with these blood components.
In this study, two storage lesions, potassium levels and
hemolysis were analyzed in irradiated and non-irradiated
PRBCs in order to determine the inﬂuence of irradiation. The
increase in potassium levels observed in both groups, but sig-
niﬁcantly more  pronounced in irradiated PRBCs from Day 7 of
storage, was gradual and linear over time as has been reported
in the literature.25 Given the low degree of hemolysis (lower
than 0.4%), we  believe that increased potassium levels may
not be associated with hemolysis, but with the increase in the
permeability of the plasma membrane to ions, an occurrence
that was reported by Moreira et al.26
The increase in potassium after irradiation was also
observed by Janatpour et al.,9 who found a value of
108.7 mequiv./L in PRBC units irradiated by a linear accelera-
tor at a dose of 25 Gy on Day 28. Similar results were found
by Bashir et al.10 Transiently increased potassium levels in
transfused patients occur due to their redistribution in the
body. The number of transfusions, hypovolemia, PRBC storage
time, PRBC irradiation, and the infusion time are critical risk
factors for hyperkalemia.25 As there is no speciﬁc reference
value for potassium levels to compare the quality in irradiated
PRBC bags7,13 and given that the values found in this study did
not differ from those observed by other authors,7,10,25 we  con-
cluded that irradiated PRBCs are suitable for transfusion up
to the 28th day after irradiation, which is in accordance with
current legislation in Brazil.
There was a gradual and linear increase in hemolysis dur-
ing storage, however, with no signiﬁcant difference between
irradiated and non-irradiated PRBCs. We also found that, even
in irradiated PRBCs, the degree of hemolysis was signiﬁcantly
lower than the recommended limit of 0.8%.7,13
Conclusions
In summary, the process of radiation in a linear accelerator,
at an appropriate dosage and under validated conditions, is
effective to irradiate PRBCs, thereby inhibiting lymphocyte
proliferation without compromising the viability of the red
blood cells to be transfused.
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